Financial Data and Key Metrics Changes - As of March 31, 2025, the company's cash, cash equivalents, and marketable securities were approximately $707.1 million, down from $861.7 million as of December 31, 2024, reflecting normal operational expenses and nonrecurring costs associated with portfolio prioritization and workforce reduction [23][24] - Collaboration revenue for Q1 2025 was $16.6 million, compared to $28.9 million in Q1 2024, primarily due to a decrease in revenue under the Avansel license agreement [24] - R&D expenses were $108.4 million in Q1 2025, down from $111.8 million in Q1 2024, driven by lower employee-related expenses and stock-based compensation [25] Business Line Data and Key Metrics Changes - The company has dosed the first patient in its Phase 3 studies for hereditary angioedema (HAE) and hereditary ATTR with polyneuropathy, indicating significant progress in its clinical pipeline [9][10] - Enrollment in the global Phase 3 HALO study for HAE is progressing rapidly, with expectations to complete enrollment by the end of Q3 2025 [17][18] - The global Phase 3 MAGNETUDE study for ATTR with cardiomyopathy is also ahead of schedule, with over 90 sites actively enrolling patients [10][21] Market Data and Key Metrics Changes - The company is observing significant interest from both investigators and patients across its programs, indicating a high unmet need in the market for effective therapies [9][10] - The FDA granted RMAT designation for NexSee for the treatment of ATTR with cardiomyopathy, which will facilitate earlier engagement with the FDA [10][21] Company Strategy and Development Direction - The company is focused on operational excellence and aims to offer life-changing benefits through one-time therapies for severe diseases [8] - Intellia is building critical commercial foundations to bring its therapies to market quickly, with plans to file its first BLA in 2026 [14] - The company is monitoring the regulatory environment closely but has not experienced any tangible changes in its interactions with the FDA [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting or exceeding regulatory timelines and objectives, with a strong relationship with the FDA [13][14] - The company anticipates a year-over-year decline in GAAP operating expenses of 5% to 10% and expects its cash balance to fund operations into the first half of 2027 [26][42] - Management highlighted the potential for significant value creation from its lead programs and the importance of maintaining a solid balance sheet [23][24] Other Important Information - The company is restructuring its real estate portfolio to reduce costs and simplify operations, expecting nearly $50 million in cash savings from a smaller footprint [39][41] - The company is actively considering non-dilutive financing options as it approaches commercialization, including collaborations and royalty transactions [50][51] Q&A Session Summary Question: Can you provide updated metrics regarding the patient baseline characteristics in the MAGNETUDE Phase 3 trial? - Management expects more than 50% of patients to be on tafamidis in the study, which is important for demonstrating a benefit over existing treatments [30] Question: What should we expect in terms of cash burn in the next 12 to 24 months? - The average cash use is estimated to be about $95 million per quarter, with a focus on efficient operations and significant milestones ahead [35][42] Question: How should we think about the launch dynamics for the first in vivo gene editing therapy? - The company is well-positioned for an efficient market entry post-approval, with a straightforward outpatient infusion process [54][56] Question: How are you thinking about pricing for your molecules given the competitive landscape? - The company aims to price its therapies competitively while providing significant value to patients and the healthcare system [60][89] Question: Can you discuss the impact of recent drug approvals on enrollment in the MAGNETUDE study? - Enrollment remains brisk despite the introduction of new drugs, as the company’s therapy offers distinct benefits [96][100]

Financial Data and Key Metrics Changes - As of March 31, 2025, the company's cash, cash equivalents, and marketable securities were approximately $707.1 million, down from $861.7 million as of December 31, 2024, reflecting normal operational expenses and nonrecurring costs associated with portfolio prioritization and workforce reduction [22][23] - Collaboration revenue for Q1 2025 was $16.6 million, compared to $28.9 million in Q1 2024, primarily due to a decrease in revenue under the Avansel license agreement [23] - R&D expenses were $108.4 million in Q1 2025, down from $111.8 million in Q1 2024, driven by lower employee-related expenses and stock-based compensation [24] Business Line Data and Key Metrics Changes - The company has dosed the first patient in its Phase 3 studies for hereditary angioedema (HAE) and hereditary ATTR with polyneuropathy, indicating significant progress in its clinical pipeline [7][14] - Enrollment in the global Phase 3 HALO study for HAE is progressing rapidly, confirming high unmet needs despite existing treatment options [8][15] - The FDA granted RMAT designation for NexSee for the treatment of ATTR with cardiomyopathy, which is expected to enhance engagement with the FDA [8][20] Market Data and Key Metrics Changes - The company is observing significant interest from both investigators and patients across its programs, with over 90 sites actively enrolling in the Phase 3 magnitude study for ATTR with cardiomyopathy [8][20] - The market for treatments for hereditary angioedema and ATTR amyloidosis is expanding, with increasing recognition of the diseases and improved diagnostic procedures [60] Company Strategy and Development Direction - The company is focused on operational excellence and aims to provide life-changing benefits through one-time therapies for severe diseases [6][7] - Intellia is building critical commercial foundations to bring its therapies to patients quickly, with a strong emphasis on evolving into a commercially ready company [9][10] - The company plans to file its first BLA in 2026 and is monitoring the regulatory environment closely, with no current changes affecting its timelines [12][13] Management's Comments on Operating Environment and Future Outlook - Management remains confident in meeting or exceeding regulatory timelines and objectives, with a strong relationship with the FDA [12][13] - The company is closely monitoring potential implications of pending pharmaceutical tariffs but is confident in its manufacturing and distribution capabilities [13] - Management expressed optimism about the potential of its therapies to reset treatment standards for patients with HAE and ATTR [14] Other Important Information - The company expects a year-over-year decline in GAAP operating expenses of 5% to 10% in 2025, with sufficient cash to fund operations into the first half of 2027 [25][36] - The company is undergoing a restructuring process aimed at reducing its real estate footprint and workforce, which is expected to yield significant cost savings [22][39] Q&A Session Summary Question: Update on magnitude Phase 3 trial enrollment and patient baseline characteristics - Management indicated that over 50% of patients in the study are expected to be on tafamidis, which is important for demonstrating the drug's benefit over existing treatments [30] Question: Cash burn and operating expenses expectations - The average cash use is estimated at $95 million per quarter for 2025 and 2026, with a focus on efficient operations and significant cost savings from real estate transactions [36][42] Question: Launch dynamics for the first in vivo gene editing therapy - The company is building a commercial organization with insights from prior one-time therapies, expecting efficient patient access post-approval [54][56] Question: Pricing strategy in light of competitive landscape - The company is focused on providing a competitive price for its one-time treatment, considering the significant cost savings for payers compared to chronic therapies [88][89] Question: Enrollment impact from new drugs in the market - Despite the approval of new drugs, the company has maintained brisk enrollment in its studies, with physicians seeing the potential for significant benefits from its therapies [95][96]

Exhibit 99.1 Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., May 8, 2025 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the first quarter ended March 31, 2025. "Intellia is full steam ahead and making excellent progress across its clinical programs," said Intel ...

Core Insights - Intellia Therapeutics reported significant progress in its clinical programs, including the initiation of Phase 3 studies for hereditary angioedema (HAE) and hereditary ATTR amyloidosis with polyneuropathy [2][5] - The company ended Q1 2025 with approximately $707.1 million in cash, expected to fund operations into the first half of 2027 [5][10] - Collaboration revenue decreased to $16.6 million in Q1 2025 from $28.9 million in Q1 2024, primarily due to a reduction in revenue from the AvenCell license [10][16] Operational Highlights - The first patients were dosed in the Phase 3 HAELO study for hereditary angioedema and the MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy [2][5] - Enrollment in the global Phase 3 MAGNITUDE trial for ATTR with cardiomyopathy is progressing ahead of projections, with expectations to exceed 550 patients by year-end [9][10] - Upcoming presentations include longer-term data from the Phase 1 study of NTLA-2002 at the EAACI Congress in June 2025 [2][6] Financial Results - Cash, cash equivalents, and marketable securities decreased from $861.7 million as of December 31, 2024, to $707.1 million as of March 31, 2025 [10][18] - Research and development expenses were $108.4 million in Q1 2025, a slight decrease from $111.8 million in Q1 2024 [10][16] - The net loss for Q1 2025 was $114.3 million, compared to a net loss of $107.4 million in Q1 2024 [10][16] Upcoming Events - Intellia will participate in several conferences, including the Bank of America Securities Health Care Conference on May 13, 2025, and the EAACI Congress on June 15, 2025 [10][12]

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) is showing potential for a bullish trend following a breakout above the 50-day moving average, indicating a key level of support [1][2]. Technical Analysis - NTLA has experienced a rally of 21.5% over the past four weeks, suggesting positive momentum [2]. - The 50-day simple moving average is a critical indicator for traders, marking the initial point of an up or down trend [2]. Earnings Estimates - There have been three upward revisions in NTLA's earnings estimates for the current fiscal year, with no downward revisions, indicating strong investor confidence [3]. - The consensus estimate for NTLA has also increased, further supporting the bullish outlook [3].

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants sh ...

Intellia Therapeutics, Inc. (NTLA) closed the last trading session at $8.48, gaining 19.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.79 indicates a 392.8% upside potential.The mean estimate comprises 24 short-term price targets with a standard deviation of $27.61. While the lowest estimate of $9 indicates a 6.1% increase from the current price level, the most optimistic a ...

SAN DIEGO, April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of thoseNASDAQ: NTLA shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.On February 11, 2025, aNASDAQ: NTLA investor filed a lawsuit ag ...

Core Viewpoint - A class action lawsuit has been filed against Intellia Therapeutics for alleged violations of federal securities laws, specifically related to misleading statements about the development of its drug NTLA-3001 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Intellia provided false and misleading information regarding the viability of NTLA-3001, leading investors to believe that the company had reliable data on its development and marketing [2]. - It is alleged that the company's reports on timelines for future studies were not sustainable due to high costs and inefficiencies in delivery methods [2]. - The company reportedly struggled to provide timely doses of NTLA-3001 and maintain adequate staffing levels [2]. Group 2: Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [3]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [3].

Core Viewpoint - A class action lawsuit has been filed against Intellia Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about the development of its drug NTLA-3001 [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that Intellia made false and misleading statements regarding its drug development and marketing strategies, particularly concerning NTLA-3001 [4]. - Investors who purchased Intellia's securities between July 30, 2024, and January 8, 2025, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning that potential class members are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Intellia provided investors with a false impression of having reliable information about NTLA-3001's development [4]. - It is claimed that the company's reports on timelines for future studies were unsustainable due to high costs and inefficient delivery methods [4]. - The company reportedly struggled to provide timely doses of NTLA-3001 and maintain adequate staffing levels, leading to materially misleading public statements [4].